Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.55 |
| ▸ | PGK1 | P00558 | 1/20 | 0.51 |
| ▸ | PGK2 | P07205 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198497 | 0.93 | ADORA2A (0.59) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL2218888 | 0.89 | ADORA2A (0.70) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL8970895 | 0.86 | ADORA2A (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL8970907 | 0.86 | ADORA2A (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL17198478 | 0.85 | ALDH1A1 (0.47) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL16081039 | 0.85 | ADORA2A (0.59) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL19186882 | 0.85 | ADORA2A (0.59) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL13468488 | 0.85 | ADORA2A (0.59) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL17198491 | 0.84 | LMNA (0.61) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL16081038 | 0.82 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | ADORA2A 122/4885ADORA2B 195/4885ADORA3 139/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | ADORA2A 111/4885ADORA2B 188/4885ADORA3 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.